Skip to main content
    U

    United Therapeutics Corporation (UTHR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $587.88
    -3.29 (-0.56%)

    Market Cap: $25.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    United Therapeutics Corporation (UTHR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    United Therapeutics (UTHR) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, United Therapeutics reported EPS of $5.71, below the $5.85 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -13.47%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$6.89
    Range$2.99 - $13.46
    16 analysts
    Revenue Consensus
    $879.42M
    Range$679.32M - $1.21B
    15 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$6.53
    Range$5.21 - $7.41
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$6.41+1.9%
    60d ago$6.33+3.1%
    30d ago$6.48+0.8%
    7d ago$7.29-10.4%
    Current$6.53
    Revenue Consensus
    $790.07M
    Range$688.00M - $849.73M
    6 analysts

    Next Report

    UTHR has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.5% below the $7.70 reported for the quarter ended Dec 31, 2025.

    UTHR Earnings Call

    The latest UTHR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, UTHR beat 19, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $832.50M, up 4.1% from $799.50M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$5.71$5.85$4.40 - $7.26-2.39%Miss-20.3%142 up, 3 downNov 4, 2026$832.50M
    Jun 30, 2026$7.27$6.82$6.07 - $7.76+6.60%Beat+13.4%121 up, 1 downAug 5, 2026$783.30M
    Mar 31, 2026$5.82$6.86$6.36 - $7.41-15.16%Miss-12.2%121 up, 3 downMay 6, 2026$781.50M
    Dec 31, 2025$7.70$7.10$3.01 - $7.94+8.45%Beat+24.4%120 up, 0 downFeb 25, 2026$790.20M
    Sep 30, 2025$7.16$6.96$6.08 - $7.67+2.87%Beat+1.3%121 up, 1 downOct 29, 2025$799.50M
    Jun 30, 2025$6.41$7.30$5.92 - $7.43-12.19%Miss+9.6%111 up, 2 downJul 30, 2025$798.60M
    Mar 31, 2025$6.63$6.54$5.35 - $7.07+1.38%Beat+7.5%10N/AApr 30, 2025$794.40M
    Dec 31, 2024$6.19$6.27$5.03 - $7.04-1.23%Miss+42.0%121 up, 1 downFeb 26, 2025$735.90M
    Sep 30, 2024$7.07$7.12$5.41 - $7.41-0.70%Miss+31.4%132 up, 0 downOct 30, 2024$748.90M
    Jun 30, 2024$5.85$6.41$5.59 - $7.47-8.74%Miss+11.6%125 up, 1 downJul 31, 2024$714.90M
    Mar 31, 2024$6.17$5.59$4.75 - $6.53+10.38%Beat+27.0%131 up, 0 downMay 1, 2024$677.70M
    Dec 31, 2023$4.36$4.19$2.97 - $5.40+4.06%Beat+63.3%141 up, 1 downFeb 21, 2024$614.70M
    Sep 30, 2023$5.38$5.04$4.01 - $5.67+6.75%Beat+9.6%111 up, 0 downNov 1, 2023$609.40M
    Jun 30, 2023$5.24$4.78N/A+9.62%Beat+51.4%112 up, 0 downAug 2, 2023$596.50M
    Mar 31, 2023$4.86$4.71$3.96 - $4.99+3.18%Beat-3.4%121 up, 0 downMay 3, 2023$506.90M
    Dec 31, 2022$2.67$4.51$3.34 - $5.23-40.80%Miss+13.6%111 up, 0 downFeb 22, 2023$491.50M
    Sep 30, 2022$4.91$3.77$2.90 - $4.86+30.24%Beat+43.6%111 up, 1 downNov 2, 2022$516.00M
    Jun 30, 2022$3.46$4.54$3.42 - $4.63-23.79%Miss-15.4%90 up, 2 downAug 3, 2022$466.90M
    Mar 31, 2022$5.03$3.07$2.27 - $3.99+63.84%Beat+44.1%91 up, 0 downMay 4, 2022$461.90M
    Dec 31, 2021$2.35$3.72$3.40 - $4.07-36.83%Miss+7.3%8N/AFeb 24, 2022$415.20M
    Sep 30, 2021$3.42$3.58$3.12 - $4.26-4.47%Miss-11.9%7N/ANov 3, 2021$444.70M
    Jun 30, 2021$4.09$3.56N/A+14.89%Beat+11.1%7N/AAug 4, 2021$446.50M
    Mar 31, 2021$3.49$3.49$2.37 - $3.610.00%In line-3.3%8N/AMay 5, 2021$379.10M
    Dec 31, 2020$2.19$3.14$2.70 - $3.76-30.25%Miss+82.5%8N/AFeb 24, 2021$1.13B
    Sep 30, 2020$3.88$3.34$1.92 - $3.49+16.17%Beat+1.3%8N/AOct 28, 2020N/A
    Jun 30, 2020$3.68$3.28$2.16 - $3.53+12.20%Beat+1.4%7N/AJul 29, 2020N/A
    Mar 31, 2020$3.61$3.39N/A+6.49%BeatN/A8N/AApr 29, 2020$356.30M
    Dec 31, 2019$1.20$2.68$1.53 - $3.35-55.22%Miss-18.9%6N/AFeb 26, 2020$311.10M
    Sep 30, 2019$3.83$2.90$1.88 - $3.23+32.07%Beat+58.3%7N/AOct 30, 2019$401.50M
    Jun 30, 2019$3.63$2.74$1.90 - $3.07+32.48%Beat-16.7%8N/AJul 31, 2019$373.60M
    Mar 31, 2019-$11.32$2.77$2.13 - $3.73-508.66%Miss-401.1%9N/AMay 1, 2019$362.60M
    Dec 31, 2018$1.48$2.55$1.82 - $3.07-41.96%Miss-62.0%8N/AFeb 27, 2019$381.40M
    Sep 30, 2018$2.42$3.03$2.45 - $3.87-20.13%Miss-48.4%7N/AOct 31, 2018$412.70M
    Jun 30, 2018$4.36$3.42$2.55 - $3.94+27.49%Beat-0.2%7N/AAug 1, 2018$444.50M
    Mar 31, 2018$3.76$4.00$2.65 - $4.46-6.00%Miss+4.2%8N/AMay 2, 2018$389.20M
    Dec 31, 2017$3.89$3.89$2.84 - $4.870.00%In line+56.2%9N/AFeb 21, 2018$464.70M
    Sep 30, 2017$4.69$4.80N/A-2.29%Miss+7.6%10N/AOct 25, 2017$445.50M
    Jun 30, 2017$4.37$3.66$2.85 - $4.09+19.40%Beat-0.5%9N/AJul 27, 2017$444.60M
    Mar 31, 2017$3.61$3.82N/A-5.50%Miss+19.5%N/AN/AApr 26, 2017$370.50M
    Dec 31, 2016$2.49$3.61N/A-31.02%Miss+18.6%N/AN/AFeb 22, 2017$409.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $27.90, up 10.4% from the year before. It was $14.26 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$27.90+10.4%
    Dec 31, 2024$25.28+27.4%
    Dec 31, 2023$19.84+23.5%
    Dec 31, 2022$16.07+20.4%
    Dec 31, 2021$13.35N/A
    Dec 31, 2020$13.36N/A
    Dec 31, 2019-$2.66-122.1%
    Dec 31, 2018$12.02-27.4%
    Dec 31, 2017$16.56+16.1%
    Dec 31, 2016$14.26N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,17915
    2026Q2Jun 30, 20264,13614
    2026Q1Mar 31, 20264,21713
    2025Q4Dec 31, 20253,7339
    2025Q3Sep 30, 20253,53912
    2025Q2Jun 30, 20256,39616
    2025Q1Mar 31, 20254,06812
    2024Q4Dec 31, 20244,27411

    2026Q3 Earnings Call

    Opening remarks

    Harry Silvers Investor Relations Thank you, Krista. Good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Third Quarter 2026 Corporate Update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, Michael Benkowitz, our President and Chief Operating Officer, James Edgemond, our Chief Financial Officer and Treasurer, Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation, and Pat Poisson, our Executive Vice President of Strategic Development. Note that James Edgemond and I will participate in a fireside chat and one-on-one sessions at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference in London on November 16th and 17th, respectively. Additionally, members from our management team will participate in a fireside chat and one-on-one meetings at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco in January of next year. Our scientific, commercial, and medical affairs teams will be present at PHenomenal Hope 2026 on December 4th in Boston and at the Pulmonary Vascular Research Institute Annual Congress in Bangkok in late January of next year. I will turn the webcast over to Martine for an overview of our development pipeline and business activities. Martine.

    Martine Rothblatt Chairperson and CEO Thank you, Harry, and good morning, everyone. We have slides available for reference, and I encourage you to review those at your leisure. I am not going to speak directly to the slides. As we look back on the third quarter, I am incredibly proud of what our teams have accomplished. We executed at a high level across our business and across our company, delivering for patients while advancing one of the most ambitious growth strategies in biotechnology. The significance of this quarter extends beyond any individual result or milestone. It reflects the broader transformation underway at United Therapeutics as we build a comprehensive cardiopulmonary and respiratory medicine franchise capable of reaching dramatically more patients than ever before. For most of our history, UT has been known as a pulmonary hypertension company.

    Frequently Asked Questions About UTHR

    When is United Therapeutics's next earnings date?

    United Therapeutics's next earnings report is expected for Feb 23, 2027.

    Did UTHR beat earnings estimates last quarter?

    No. United Therapeutics reported EPS of $5.71 for the quarter ended Sep 30, 2026, below the $5.85 estimate by 2.39%.

    What EPS do analysts expect from UTHR next quarter?

    The consensus EPS estimate for United Therapeutics for the quarter ending Dec 31, 2026 is $6.89 from 16 analysts, with estimates from $2.99 to $13.46.

    How often does UTHR beat earnings estimates?

    United Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.46%.